This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Zuellig Pharma Ltd.
Zuellig Pharma Ltd., headquartered in Hong Kong, is a leading healthcare services provider in Asia, specialising in pharmaceutical distribution and supply chain solutions. Founded in 1922, the company has established a strong presence across major operational regions, including Southeast Asia and Greater China, making it a pivotal player in the healthcare industry. With a focus on enhancing patient access to medicines, Zuellig Pharma offers a range of core services, including logistics, regulatory support, and commercialisation strategies for pharmaceutical companies. Its commitment to innovation and efficiency sets it apart in a competitive market. Notably, Zuellig Pharma has achieved significant milestones, such as the implementation of advanced digital solutions to streamline operations, reinforcing its position as a trusted partner in the healthcare ecosystem.
DitchCarbon Score
How does Zuellig Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zuellig Pharma Ltd.'s score of 43 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zuellig Pharma Ltd., headquartered in Hong Kong, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Zuellig Pharma Holdings, which may influence its climate commitments and performance metrics. As of now, there are no documented reduction targets or climate pledges from Zuellig Pharma Ltd. This lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. Given the absence of direct emissions data, it is essential to note that the broader industry context is increasingly focused on sustainability and carbon reduction. Many companies are adopting Science-Based Targets Initiative (SBTi) frameworks and committing to net-zero goals, which may influence Zuellig Pharma Ltd.'s future commitments and strategies. As the company progresses, it may look to establish measurable targets and initiatives to align with industry standards and expectations for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 9,551,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,061,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 341,689,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zuellig Pharma Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
